Dialysis modality and mortality in polycystic kidney disease.
Dialysis modality and mortality in polycystic kidney disease.
复制标题
多囊肾病的透析方式和死亡率。
DOI：
10.1111/hdi.12673
复制
发表时间：
2018
影响因子：
1.3
通讯作者：
Xue Cheng
中科院分区：
文献类型：
--
作者：
Zhou Chenchen;Gu Yaodong;Mei Changlin;Dai Bing;Wang Yi;Xue Cheng
简介：确定血液透析（HD）和腹膜透析（PD）之间的适当方式是多囊肾病（PKD）患者中尚未解决的问题。本研究的目的是说明是否死亡率和生存率是不同的个人接受HD比较PD.Methods：我们检索PubMed，EMBASE，和中国国家知识基础设施队列研究涉及PKD患者的终末期肾病和比较HD与PD。我们计算了二分数据的合并风险比（RR）和95%置信区间（CI）。主要结果是死亡率和生存率（不是技术生存率）。结果：8项研究涉及7685例PKD患者。HD和PD之间的死亡率（RR 1.06，95% CI 0.84-1.34，P = 0.61）和5年生存率（RR 0.99，95% CI 0.80-1.22，P = 0.90）无显著差异。腹膜透析与腹腔感染和疝的高风险无关。HD组肾囊肿出血发生率高于HD组（RR 2.53，95% CI 1.05-6.12，P = 0.04）。对于接受肾脏替代治疗的PKD患者，PD可能与HD一样成功。
Introduction: Identifying the appropriate modality between hemodialysis (HD) and peritoneal dialysis (PD) is an unresolved issue in polycystic kidney disease (PKD) patients. This study aims to illustrate whether the mortality and survival are different among individuals receiving HD comparing PD.Methods: We searched PubMed, EMBASE, and China National Knowledge Infrastructure about cohort studies involving PKD patients with end stage renal disease and comparing HD with PD. We calculated pooled risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data. Primary outcomes were the mortality and survival (not the technique survival).Findings: Eight studies involving 7685 PKD patients were identified. There were no significant differences in mortality (RR 1.06, 95% CI 0.84–1.34, P = 0.61) and 5‐year survival rate (RR 0.99, 95% CI 0.80–1.22, P = 0.90) between HD and PD. PD was not associated with higher risks of abdominal infections and hernia. However, HD was associated with a higher incidence of renal cyst hemorrhage (RR 2.53, 95% CI 1.05–6.12, P = 0.04).Discussion: There are no significant differences of mortality and survival between different dialysis modalities in PKD. PD may be as successful as HD for PKD patients receiving renal replacement therapy.